Molina Healthcare Inc.

• Valuation1.5 / 10
• Management7.5 / 10
• Balance Sheet6 / 10
• Profitability1.5 / 10
• Revenue Growth2.5 / 10
• Risk Assessment7.5 / 10
• Competitive Moat6.5 / 10
• Earnings Quality1.5 / 10
• Capital Efficiency4.5 / 10

The central risk confronting the business is persistent underwriting margin compression from lagging state Medicaid rate updates. Management guided full-year 2026 Medicaid rates at 4% against medical cost trends of 5%. If state capitation rate increases fail to bridge this 100-basis-point deficit and post-redetermination member acuity drives the Medicaid Medical Care Ratio above 93.5%, annual pretax earnings would contract by approximately USD 350M to USD 400M, while ongoing cumulative Medicaid enrollment runoff of 8% to 9% erodes fixed administrative cost absorption.⁵

Conversely, the principal operational catalyst that could support earnings recovery is the combination of Medicaid rate catch-up and non-recurring loss elimination. Management is exiting discontinued Medicare Advantage products ($1.00 per share 2026 drag) and pruning individual Marketplace exchanges to eliminate a $0.75 per share loss. Coupled with robust outperformance in Medicare duals ($1.25 per share contribution on $5B revenue), operating margin expansion toward normalized levels could lift earnings per share toward consensus FY2027 expectations of $8.55. However, even achieving Potential value of USD 188.58 remains well below the report-date price of USD 209.19.^1,4,5

Management acknowledged 30% price increases retained high-utilization members, and medical expenses are not risk-adjustable. Persistent adverse selection could keep underwriting losses above -$0.50/share into FY2027, preventing post-trough earnings normalization.⁵

Marketplace Segment Loss Per Share

Confirms that 30% price increases have caused structural adverse selection by retaining sicker, non-risk-adjustable members, delaying earnings normalization.

Obecnie:-$0.75 per share guided for FY2026

Our Bull scenario projects Potential value of $188.58, representing an implied return of -9.9% from $209.19 with an assigned probability of 20.0%. This upside pathway requires accelerated state rate updates that rapidly restore Medicaid pretax margins above targeted thresholds, complete elimination of exchange underwriting deficits, and aggressive top-line compounding driven by major state contract procurement wins and dual-eligible outperformance. This scenario would be disconfirmed if state procurement renewal awards are delayed, if competing commercial plans undercut pricing, or if medical cost trends accelerate in high-acuity populations.

Measures whether dramatic average price increases and geographic footprint reduction into core states successfully eliminate exchange drag without retaining disproportionately high-cost lives.

Medicaid pretax operating margin is guided to 1.2% in FY2026 with a medical care ratio of 92.9% as 4% rate updates trail 5% medical cost trends.

Underwriting profitability has reached cyclical lows; closing the 90 bps margin gap back toward 2.5% provides the primary operational driver for post-FY2026 earnings expansion.